0001209191-16-142260.txt : 20160921
0001209191-16-142260.hdr.sgml : 20160921
20160921160842
ACCESSION NUMBER: 0001209191-16-142260
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20160920
FILED AS OF DATE: 20160921
DATE AS OF CHANGE: 20160921
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ARCA biopharma, Inc.
CENTRAL INDEX KEY: 0000907654
STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
IRS NUMBER: 363855489
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 11080 CIRCLEPOINT ROAD
STREET 2: SUITE 140
CITY: WESTMINSTER
STATE: CO
ZIP: 80020
BUSINESS PHONE: 720-940-2200
MAIL ADDRESS:
STREET 1: 11080 CIRCLEPOINT ROAD
STREET 2: SUITE 140
CITY: WESTMINSTER
STATE: CO
ZIP: 80020
FORMER COMPANY:
FORMER CONFORMED NAME: NUVELO INC
DATE OF NAME CHANGE: 20030203
FORMER COMPANY:
FORMER CONFORMED NAME: HYSEQ INC
DATE OF NAME CHANGE: 19970610
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Keuer Thomas A
CENTRAL INDEX KEY: 0001290482
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-22873
FILM NUMBER: 161895731
MAIL ADDRESS:
STREET 1: C/O ARCA BIOPHARMA, INC.
STREET 2: 11080 CIRCLEPOINT RD, STE 140
CITY: WESTMINSTER
STATE: CO
ZIP: 80020
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2016-09-20
0
0000907654
ARCA biopharma, Inc.
ABIO
0001290482
Keuer Thomas A
11080 CIRCLEPOINT ROAD
SUITE 140
WESTMINSTER
CO
80020
0
1
0
0
Chief Operating Officer
Common Stock
2016-09-20
4
S
0
714
2.89
D
15383
D
Represents shares of common stock sold pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person with respect to the vesting of previously reported Restricted Stock Units ("RSUs") granted to the Reporting Person under the Issuer's 2013 Amended and Restated Equity Incentive Plan (the "Plan")
The price represents the weighted average sale price for multiple transactions reported on this line. The prices of the transactions ranged from $2.88 to $2.89. Upon request of the SEC staff, ARCA biopharma, Inc. (the "Company") or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold at each separate price.
Includes (i) remaining 1,429 previously reported shares issued as RSUs under the Plan that vests on 10/15/16, (ii) remaining 2,443 previously reported shares issued as RSUs under the Plan that vest in two equal annual installments beginning on 2/27/17, and (iii) 2,414 previously reported shares issued as RSUs under the Plan that vest in two equal annual installments beginning 4/2/17, provided that the Reporting Person's continuous service to the Issuer has not been terminated as defined under the Plan; and 9,097 previously reported shares of common stock owned.
/s/ Thomas A. Keuer
2016-09-21